Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma

Small fluorescent molecules for monitoring autophagic flux

(2018) Hidefumi Iwashita et al.   FEBS LETTERS

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial

(2017) Angela Alistar et al.   LANCET ONCOLOGY

The emerging role and targetability of the TCA cycle in cancer metabolism

(2017) Nicole M. Anderson et al.   Protein & Cell

Hydroxychloroquine in systemic lupus erythematosus (SLE)

(2016) C. Ponticelli et al.   Expert Opinion On Drug Safety

The role for autophagy in cancer

(2015) Eileen White   JOURNAL OF CLINICAL INVESTIGATION

A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies

(2014) T. S. Pardee et al.   CLINICAL CANCER RESEARCH

Sentinel node biopsy in soft tissue sarcoma subtypes with a high propensity for regional lymphatic spread--results of a large prospective trial

(2013) D. Andreou et al.   ANNALS OF ONCOLOGY

A WWOX-binding molecule, transmembrane protein 207, is related to the invasiveness of gastric signet-ring cell carcinoma

(2012) Tamotsu Takeuchi et al.   CARCINOGENESIS

Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo

(2011) Zuzana Zachar et al.   JOURNAL OF MOLECULAR MEDICINE-JMM